CJC-1295 & Ipamorelin

What the Published Literature Contains

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-234 cited sources

The short answer

The core literature is small and unusually clinical for this field: two 2006 human studies in the Journal of Clinical Endocrinology and Metabolism on CJC-1295, and Raun's 1998 paper establishing ipamorelin's selectivity. There is comparatively little beyond them.

Key facts

Teichman 2006
CJC-1295 PK/PD in healthy adults
Ionescu & Frohman 2006
Pulsatility under continuous stimulation
Raun 1998
Ipamorelin selectivity
Human data
Present, unlike most of this library
Registered trials
None currently established
Search terms
Also NNC 26-0161, GRF(1-29)

A small literature with an unusual composition

Most research peptides have a large rodent literature and no human data. This pair has the opposite profile: a modest number of papers, two of which are controlled human studies in a mainstream endocrinology journal. Volume is low; quality of the core references is comparatively high.

The three papers that matter

Teichman and colleagues, JCEM 2006, on prolonged GH and IGF-I stimulation by CJC-1295 with DAC in healthy adults. Ionescu and Frohman, JCEM 2006, on whether pulsatile GH secretion survives continuous stimulation. Raun and colleagues, European Journal of Endocrinology 1998, establishing ipamorelin as the first selective growth hormone secretagogue. Nearly everything else cites one of these.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £42.99

What is absent

Registered interventional trials currently under way, unlike BPC-157, which has a Phase 2 recruiting. Long-term data of any kind. And studies of the combination with the single-agent arms that would be needed to say anything about additivity. The gaps are specific rather than general.

Searching it

CJC-1295 finds the compound directly. GRF(1-29) and sermorelin surface the wider GHRH-analogue literature that gives context. NNC 26-0161 finds ipamorelin's development-era records. Searching only the product names returns a mix of commercial content and the handful of primary papers.

How this category compares within the library

Better human pharmacokinetic data than GHK-Cu, TB-500, DSIP, Semax or Selank. Less clinical development than BPC-157, which has a Phase 2 recruiting. And far less than the incretins, which have outcome trials with tens of thousands of participants. A useful middle position, and an honest one to state.

Frequently asked questions

Is there human data for these compounds?

Yes. Two 2006 studies in the Journal of Clinical Endocrinology and Metabolism examined CJC-1295 in healthy adults, which is more than most compounds in this library have.

Are there ongoing trials?

None currently established, unlike BPC-157 which has a Phase 2 recruiting.

What should I search besides the product names?

GRF(1-29) and sermorelin for the GHRH-analogue context, and NNC 26-0161 for ipamorelin's development records.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More CJC-1295 & Ipamorelin articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.